Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2022 / Sep / Retinal Roadbook… and Other News
Retina Research & Innovations

Retinal Roadbook… and Other News

A brief journey through the latest retina research

By Geoffrey Potjewyd 9/8/2022 3 min read

Share

Credit: Image sourced from Shutterstock.com

Baby blue. A multinational study led by researchers at the University of Leicester, UK, has deciphered how genetics influence visual development in developing babies’ eyes – more specifically looking at genes associated with arrested development of the fovea (1). They investigated a cohort of almost one thousand people with confirmed genetic disorders associated with foveal hypoplasia - classifying how foveal development correlates to genotype and the visual outcome.

Extending family. NEI researchers have identified a novel early-onset macular dystrophy that occurs as a result of new mutations in the gene TIMP3, already known to be associated with the disease (2). These new mutations were not in the mature protein, but in the signal peptide preventing the immature protein from being cleaved.

Marked targets. Fibroblasts from primary open angle glaucoma patients were reprogrammed into stem cells and differentiated to form a model of the retina and optic nerve to identify unknown genetic markers of glaucoma (3). 312 genetic variants were associated with the target retinal cells and 97 genetic clusters were linked to glaucoma caused damage.

Pixel by pixel. A machine learning model uses a pixel stratification approach to comprehensively reconstruct and examine the vitreous anatomy in 3D. The technique produces high quality 3D movies, similar to triamcinolone-assisted vitrectomy or postmortem dye injection (4). By examining the vitreous structure beyond the vitreoretinal interface there are applications for many macular diseases and diabetic retinopathy. The approach uses swept source OCT (SS-OCT) scans that are analyzed through Fiji (is just image J) to stack into cubic voxels. After processing the signals from the vitreous gel, spaces within, and interfaces between them, two classes of “Septa” and “Other” were defined - these pixels were assigned to either of the classes, which in turn trained the classifier system. 

Intelligent reclassification. A new proposed framework for classifying diabetic retinopathy uses OCT and OCT-A with AI to provide specialized classification, all under one imaging modality (5).

Safe but inefficient. An early LHON clinical trial shows that gene therapy treatment trial is safe but not effective at improving or slowing vision loss (6).

Plateau in progress. Although visual impairment in adults with diabetes was in decline since 2000, this may have plateaued from 2012 (7). The study performed by the CDC provides insights into vision impairment in adults with diabetes.

Through thick and thin. Retinal nerve fiber layer thickness is associated with cognitive function and subsequent cognitive decline (8). This information could be applied to OCT eye tests as a predictive biomarker for cognitive function in older patients. 

References

  1. HJ Kuht et al., Ophthalmology, 129, 708 (2022). PMID: 35157951.
  2. B Guan et al., JAMA Ophthalmol, 140, 730 (2022). PMID: 35679059.
  3. M Daniszewski et al., Cell Genomics, 2, 8 (2022). Doi: 10.1016/j.xgen.2022.100142.
  4. A Thi et al., Transl Vis Sci Technol, 11, 3 (2022). PMID: 35802368.
  5. P Zang et al., Transl Vis Sci Technol, 11, 10 (2022). PMID: 35822949.
  6. BL Lam et al., Am J Ophthalmol, S0002-9394, 00088 (2022). PMID: 35271811.
  7. EA Lundeen et al., Poster Presentation at ADA (2022). Available at: https://bit.ly/3z9dRuv.
  8. HM Kim et al., JAMA Ophthalmol, 140, 683 (2022). PMID: 35616950.

About the Author(s)

Geoffrey Potjewyd

The lion’s share of my PhD was spent in the lab, and though I mostly enjoyed it (mostly), what I particularly liked was the opportunity to learn about the latest breakthroughs in research. Communicating science to a wider audience allows me to scratch that itch without working all week only to find my stem cell culture has given up the ghost on the Friday (I’m not bitter). Fortunately for me, it turns out writing is actually fun – so by working for Texere I get to do it every day, whilst still being an active member of the clinical and research community.

More Articles by Geoffrey Potjewyd

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: